The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma

[1]  Yonghong Zhang,et al.  The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study , 2021, Frontiers in Oncology.

[2]  Wang Yanhan,et al.  Effect of Microvascular Invasion on the Prognosis in Hepatocellular Carcinoma and Analysis of Related Risk Factors: A Two-Center Study , 2021, Frontiers in Surgery.

[3]  Jun Liu,et al.  Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma , 2021, Frontiers in Oncology.

[4]  Xi Yu,et al.  Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma , 2021, Journal of hepatocellular carcinoma.

[5]  L. Rimassa,et al.  ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma , 2021, JHEP reports : innovation in hepatology.

[6]  S. Kubo,et al.  Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. , 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  Kaijun Huang,et al.  Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and FIB-4) Model to Predict Posthepatectomy Liver Failure Grade B-C in Patients with Hepatocellular Carcinoma , 2021, Journal of oncology.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  T. Murakami,et al.  Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. , 2021, The British journal of surgery.

[10]  D. Boll,et al.  Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models , 2020, European Radiology.

[11]  Zhi-ming Lu,et al.  Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation , 2020, Infectious Agents and Cancer.

[12]  Yan Li,et al.  Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  Lei Liu,et al.  Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases , 2020, Annals of translational medicine.

[14]  Lujun Shen,et al.  Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion , 2019, Aging.

[15]  T. Kawaguchi,et al.  Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  T. Kawaguchi,et al.  Effects of in‐hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization , 2018, Journal of gastroenterology and hepatology.

[17]  Leizhen Zheng,et al.  Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients , 2018, Cancer management and research.

[18]  Y. Fujiwara,et al.  Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.

[19]  T. Saibara,et al.  A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD , 2018, Scientific Reports.

[20]  Yan Zhang,et al.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer , 2018, Medicine.

[21]  Xinrui Zhao,et al.  Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies , 2018, Archives of Gynecology and Obstetrics.

[22]  B. Carr,et al.  Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients , 2017, The International journal of biological markers.

[23]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[24]  M. Sherman,et al.  Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis , 2015, Journal of surgical oncology.

[25]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Ryo Ashida,et al.  Preoperative Neutrophil to Lymphocyte Ratio and Prognostic Nutritional Index Predict Overall Survival After Hepatectomy for Hepatocellular Carcinoma , 2015, World Journal of Surgery.

[27]  M. Kanda,et al.  Comparison of inflammation‐based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection , 2014, Journal of hepato-biliary-pancreatic sciences.

[28]  Junfei Jin,et al.  Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection , 2014, Translational oncology.

[29]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[30]  J. Seong,et al.  Clinical usefulness of double biomarkers AFP and PIVKA‐II for subdividing prognostic groups in locally advanced hepatocellular carcinoma , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[31]  T. Ishiko,et al.  Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma , 2013, International Journal of Clinical Oncology.

[32]  S. Friedman,et al.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.

[33]  H. T. Wang,et al.  Inhibition of growth and induction of differentiation of SMMC-7721 human hepatocellular carcinoma cells by Oncostatin M. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[34]  H. Tajiri,et al.  The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma , 2013, BMC Cancer.

[35]  Masato Kato,et al.  Usefulness of a modified inflammation‐based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma , 2011, Journal of surgical oncology.

[36]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[37]  J. Izbicki,et al.  Glasgow Prognostic Score is a Predictor of Perioperative and Long-term Outcome in Patients with only Surgically Treated Esophageal Cancer , 2011, Annals of Surgical Oncology.

[38]  D. McMillan,et al.  An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer , 2008, Proceedings of the Nutrition Society.

[39]  D C McMillan,et al.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer , 2003, British Journal of Cancer.